- Report
- October 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1097EUR$1,250USD£955GBP
- Report
- September 2025
- 140 Pages
Global
From €3510EUR$3,999USD£3,054GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3292EUR$3,750USD£2,864GBP
- Report
- May 2024
- 129 Pages
Global
From €3510EUR$3,999USD£3,054GBP
Ambisome is a brand of liposomal amphotericin B, an antifungal drug used to treat a variety of fungal infections. It is used to treat serious fungal infections in patients with weakened immune systems, such as those with HIV/AIDS, cancer, or organ transplants. Ambisome is a polyene antifungal drug, meaning it works by binding to the cell membrane of the fungus and disrupting its structure. It is generally used as a last resort when other antifungal drugs have failed.
Ambisome is part of the larger Infectious Diseases Drugs market, which includes a variety of drugs used to treat bacterial, viral, and fungal infections. These drugs are used to treat a wide range of infections, from common colds to life-threatening illnesses.
Some companies in the Infectious Diseases Drugs market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more
